PhoenixBio Co (TSE:6190) Other Stockholders Equity: 円93 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:6190 PhoenixBio Co Ltd TSE:6190
56 GF Score
Price 円346.00
GF Value 円355.55
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is PhoenixBio Co Other Stockholders Equity?

PhoenixBio Co TSE:6190 -2.26% 56 Other Stockholders Equity is 円93 Mil as of Mar. 2026. GuruFocus rates TSE:6190 with a GF Score™ of 56/100 and a GF Value™ of 円355.55 (Fairly Valued). The stock has 5 warning signs investors should review.

PhoenixBio Co's Other Stockholders Equity for the quarter that ended in Mar. 2026 was 円93 Mil.

PhoenixBio Co's quarterly Other Stockholders Equity declined from Mar. 2025 (円39 Mil) to Sep. 2025 (円35 Mil) but then increased from Sep. 2025 (円35 Mil) to Mar. 2026 (円93 Mil).

PhoenixBio Co's annual Other Stockholders Equity increased from Mar. 2024 (円36 Mil) to Mar. 2025 (円39 Mil) and increased from Mar. 2025 (円39 Mil) to Mar. 2026 (円93 Mil).

PhoenixBio Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for PhoenixBio Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhoenixBio Co Other Stockholders Equity Chart

PhoenixBio Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.87 -2.75 36.20 38.73 93.38

PhoenixBio Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.20 37.52 38.73 35.14 93.38
TSE:6190
56GF Score
PhoenixBio Co Ltd TSE:6190
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhoenixBio Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of 円93 Mil mean?
PhoenixBio Co (TSE:6190) has a Other Stockholders Equity of 円93 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on PhoenixBio Co and its competitors.
Is PhoenixBio Co's Other Stockholders Equity too high?
PhoenixBio Co's current Other Stockholders Equity is 円93 Mil. Overall, PhoenixBio Co has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Other Stockholders Equity compare to VRTX and REGN?
PhoenixBio Co's Other Stockholders Equity of 円93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on PhoenixBio Co and its competitors. PhoenixBio Co's current Other Stockholders Equity is 円93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円355.55, compared to a current price of 円346.00 — trading 2.7% below its estimated fair value. The current Other Stockholders Equity is 円93 Mil. PhoenixBio Co's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Other Stockholders Equity is 円93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhoenixBio Co (TSE:6190) Overvalued in 2026?

Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued. The current stock price of 円346.00 is trading 2.7% below its estimated GF Value™ of 円355.55. GuruFocus considers PhoenixBio Co to be Fairly Valued.

Key valuation signals for TSE:6190:

  • Other Stockholders Equity: 円93 Mil
  • GF Value™: 円355.55 vs. price of 円346.00 (2.7% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhoenixBio Co Business Description

Address 3-4-1, Kagamiyama, Hiroshima Prefecture, Higashi-Hiroshima, JPN, 739-0046
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
56GF Score

Get the complete analysis for TSE:6190

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円346.00
Price
円355.55
GF Value